Donald W. Parsons, MD, PhD
Department or Service
- Texas Medical Center
Co-Director, Brain Tumor Program
Co-Director, Cancer Genetics and Genomics Program
Director, Pediatric Center for Personal Cancer Genomics and Therapeutics
Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
|Ohio State University College of Medicine||medical school||Doctor of Medicine||2001|
|Ohio State University College of Medicine||PhD||Doctor of Philosophy, Pathology||1999|
|Johns Hopkins University / National Cancer Institute||fellowship||Neuro-Oncology||2008|
|Johns Hopkins University||fellowship||Pediatric Hematology/Oncology||2007|
|Johns Hopkins University||residency||Pediatrics||2004|
Dr. Donald Williams (Will) Parsons has distinguished himself as one of the country’s leaders in the genomics of childhood cancer, as well as a leader in pediatric neuro-oncology. Dr. Will Parsons is an associate professor of pediatrics – hematology/oncology at Baylor College of Medicine and the Texas Children’s Cancer Center. He is board-certified by the American Board of Pediatrics in both general pediatrics and pediatric hematology/oncology. He is a recognized pediatric hematologist-oncologist specializing in the care of children with brain and spinal cord tumors.
After graduating from Princeton University in 1992 with a degree in Chemistry, Dr. Will Parsons obtained his Ph.D. (Pathology) and M.D. degrees from The Ohio State University College of Medicine. He conducted his residency in pediatrics at Johns Hopkins and a fellowship in pediatric hematology-oncology as part of the combined Johns Hopkins/National Cancer Institute program. He served on the faculty at Johns Hopkins for one year prior to coming to Baylor College of Medicine in 2008.
Dr. Parsons is Co-Director of both the Brain Tumor Program and the Cancer Genetics and Genomics Program where he is also Director Pediatric Center for Personal Cancer Genomics and Therapeutics for the Cancer Center at Texas Children's Hospital. Dr. Parsons continues to be a distinguished contributor to the scientific and genomic studies conducted within the Brain Tumor and Liver Tumor Program research laboratories.
|American Association for Cancer Research (AACR)||Member|
|American Society of Clinical Oncology (ASCO)||Member|
|American Society of Pediatric Hematology and Oncology (ASPHO)||Member|
|Society of Neuro-Oncology||Member|
Dr. Parson’s research is focused on the genomic characterization of pediatric liver tumors, including hepatoblastoma and hepatocellular carcinoma, using DNA and RNA-based sequencing methods. His results will guide physicians to risk adapted treatments and may find potential targets for treatments.
Dr. Parsons’ research focuses on the clinical application of genomic technologies in pediatric cancer care. He is the co-PI of the ongoing BASIC3 (Baylor Advancing Sequencing in Childhood Cancer Care) study, a NHGRI Clinical Sequencing Exploratory Research project investigating the utility of tumor and germline whole exome sequencing for children with newly-diagnosed CNS and non-CNS solid tumors. Preliminary results of the BASIC3 study have been presented at numerous national and international scientific meetings, including ASHG 2013, AACR Pediatric Cancer 2013, AACR 2014 and ASCO 2014. His work has been instrumental in the characterization of the genetic landscapes of a variety of pediatric and adult cancers, including the identification of IDH1 and IDH2 as critical genes in gliomas and MLL2 and MLL3 in medulloblastomas. Dr. Parsons is currently engaged in genomic analyses of numerous pediatric cancers, including central nervous system tumors, sarcomas, and histiocytic disorders.
Parsons has published more than 40 scientific papers in peer-reviewed journals, including: Science, Nature, the Journal of Clinical Oncology, and the New England Journal of Medicine. He has been awarded numerous honors for his research, including the Peter A. Steck Memorial Award for Brain Tumor Research (2009). Parsons is a Graham Cancer Research Scholar at Texas Children’s Cancer Center and has received funding from multiple sources to support his work on the genetic causes of pediatric cancers, including: the Cancer Prevention Research Institute of Texas (CPRIT), the National Human Genome Research Institute (NGRI), the National Cancer Institute (NCI), the Gillson Longenbaugh Foundation, the American Brain Tumor Association, Alex’s Lemonade Stand Foundation, the American Society for Clinical Oncology (ASCO), the Doris Duke Charitable Foundation, and the Sidney Kimmel Foundation, and the Sontag Foundation. He is actively involved in a number of national organizations, and currently serves on the CNS Disease Committee of the Children’s Oncology Group and as the Co-Chair of the Biology Committee of the Pediatric Brain Tumor Consortium (PBTC).
Dr. Parsons is Co-Director of the Cancer Genetics and Genomics Program and a member of the Brain Tumor Program and Liver Tumor Program research laboratories. His research interests include: the clinical application of genomic technologies in pediatric cancer care; identification and characterization of cancer-causing mutations in pediatric tumors.